Compare TG Therapeutics Inc (TGTX) vs TTM Technologies Inc. Common Stock (TTMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TTM Technologies Inc. Common Stock — how do they compare? TG Therapeutics Inc trades at $54.9 (market cap $8.16B), while TTM Technologies Inc. Common Stock trades at $121.65 (market cap $12.38B). The key difference: TTM Technologies Inc. Common Stock is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, TTM Technologies Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and TTM Technologies Inc. Common Stock for 0 Days on average.
| TGTX | TTMI | |
|---|---|---|
Market Cap | $8.16B | $12.38B |
Volume | 1,735,121 | 2,258,598 |
Sector | Health | Technology |
52-Week High | $59.06 | $221.47 |
52-Week Low | $26.94 | $53.58 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $8.37B | $12.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TTM Technologies Inc. Common Stock
TTM Technologies manufactures printed circuit boards, radio-frequency components, and electronics assemblies. Its products are used in aerospace, defense, automotive, data center, and communications equipment.
Read more on TTMI →
